Detalles de la búsqueda
1.
The IRIS V study: pioglitazone improves systemic chronic inflammation in patients with type 2 diabetes under daily routine conditions.
Diabetes Technol Ther
; 10(3): 206-12, 2008 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-18473695
2.
Effect of simvastatin and/or pioglitazone on insulin resistance, insulin secretion, adiponectin, and proinsulin levels in nondiabetic patients at cardiovascular risk--the PIOSTAT Study.
Metabolism
; 56(4): 491-6, 2007 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-17379006
3.
Relaxin expression correlates significantly with serum changes in VEGF in response to antidiabetic treatment in male patients with type 2 diabetes mellitus.
Clin Lab
; 53(3-4): 193-8, 2007.
Artículo
en Inglés
| MEDLINE | ID: mdl-17447657
4.
Improvement of cardiovascular risk markers by pioglitazone is independent from glycemic control: results from the pioneer study.
J Am Coll Cardiol
; 45(12): 1925-31, 2005 Jun 21.
Artículo
en Inglés
| MEDLINE | ID: mdl-15963388
5.
Potential role of oral thiazolidinedione therapy in preserving beta-cell function in type 2 diabetes mellitus.
Drugs
; 65(1): 1-13, 2005.
Artículo
en Inglés
| MEDLINE | ID: mdl-15610048
6.
IRIS II study: intact proinsulin is confirmed as a highly specific indicator for insulin resistance in a large cross-sectional study design.
Diabetes Technol Ther
; 7(3): 478-86, 2005 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-15929679
7.
Analysis of the relationship between the Pro12Ala variant in the PPAR-gamma2 gene and the response rate to therapy with pioglitazone in patients with type 2 diabetes.
Diabetes Care
; 26(3): 825-31, 2003 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-12610044
8.
Fasting intact proinsulin is a highly specific predictor of insulin resistance in type 2 diabetes.
Diabetes Care
; 27(3): 682-7, 2004 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-14988285
9.
A comparison of the effects of thiazolidinediones and metformin on metabolic control in patients with type 2 diabetes mellitus.
Clin Ther
; 26(6): 805-18, 2004 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-15262452
10.
Effects of pioglitazone on metabolic control and blood pressure: a randomised study in patients with type 2 diabetes mellitus.
Curr Med Res Opin
; 19(6): 532-9, 2003.
Artículo
en Inglés
| MEDLINE | ID: mdl-14594526
11.
IRIS II Study: Sensitivity and specificity of intact proinsulin, adiponectin, and the proinsulin/adiponectin ratio as markers for insulin resistance.
Diabetes Technol Ther
; 6(6): 836-43, 2004 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-15684637
12.
Cost effectiveness of combination therapy with pioglitazone for type 2 diabetes mellitus from a german statutory healthcare perspective.
Pharmacoeconomics
; 22(5): 321-41, 2004.
Artículo
en Inglés
| MEDLINE | ID: mdl-15061682
13.
Postmarketing surveillance study of the efficacy and tolerability of pioglitazone in insulin-resistant patients with type 2 diabetes mellitus in general practice.
Clin Drug Investig
; 23(11): 725-34, 2003.
Artículo
en Inglés
| MEDLINE | ID: mdl-17536886
14.
Downregulation of the proinflammatory state of circulating mononuclear cells by short-term treatment with pioglitazone in patients with type 2 diabetes mellitus and coronary artery disease.
PPAR Res
; 2011: 647017, 2011.
Artículo
en Inglés
| MEDLINE | ID: mdl-21808640
15.
Pioglitazone lowers blood pressure in hypertensive patients with type 2 diabetes mellitus : an open, multicentre, observational study.
Clin Drug Investig
; 25(5): 337-40, 2005.
Artículo
en Inglés
| MEDLINE | ID: mdl-17532671
16.
Increased prevalence of cardiovascular disease and risk biomarkers in patients with unknown type 2 diabetes visiting cardiology specialists: results from the DIASPORA study.
Diab Vasc Dis Res
; 7(2): 145-50, 2010 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-20382778
17.
Pioglitazone improves metabolic markers in patients with type 2 diabetes independently from physical activities: results from the IRIS III study.
J Diabetes Sci Technol
; 2(2): 244-9, 2008 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-19885350
18.
Effects of pioglitazone and/or simvastatin on low density lipoprotein subfractions in non-diabetic patients with high cardiovascular risk: A sub-analysis from the PIOSTAT study.
Atherosclerosis
; 201(1): 155-62, 2008 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-18374336
19.
Anti-inflammatory effects of pioglitazone and/or simvastatin in high cardiovascular risk patients with elevated high sensitivity C-reactive protein: the PIOSTAT Study.
J Am Coll Cardiol
; 49(3): 290-7, 2007 Jan 23.
Artículo
en Inglés
| MEDLINE | ID: mdl-17239709
20.
Relaxin expression correlates significantly with serum fibrinogen variation in response to antidiabetic treatment in women with type 2 diabetes mellitus.
Gynecol Endocrinol
; 23(6): 356-60, 2007 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-17616862